medigraphic.com

2010, Number 1

Next >>

Vet Mex 2010; 41 (1)

Solubility of a compound with fasciolicidal activity: evaluation of efficacy in vitro and experimentally on infected sheep with Fasciola hepatica

Munguía XJA, Ibarra VF, Yolanda Vera MY, Rosiles MR, Romo MA, Cantó AJ, Ducoing WA

Language: English/Spanish
References: 41
Page: 1-11
PDF size: 239.29 Kb.


ABSTRACT

Compound alpha (Ca) is a benzimidazolic derivate which has shown a high fasciolicidal efficacy when it is given by oral via. Solubilization of Ca would be a suitable alternative to obtain an injectable formulation. The objectives of the present study were to evaluate the solubility of Ca in order to determine the in vitro fasciolicidal efficacy and experimentally on infected ovines. The assays of solubility quantified by high-performance liquid chromatography (HPLC), showed that beta-cyclodextrin (Β-CD) and hydroxi-propylbeta-cyclodextrin (HP-Β-CD) solubilized in 0.015% and 1.018% respectively. The solubilization for HP-Β-CD was calculated as 3.95% for 5.8 mg; 10.76% for HP-Β-CD with methanol, 39.048% for proylene-glycol (PG), 100% for glycerol formal (GF), and 100% for combined PG and GF and water in proportions of 3:2:5 and 3:2:4. In vitro evaluation using immature F. hepatica showed that Ca induced 100% efficacy 24 hours after solubilization with either GF or GF combined with PG and water. The efficacy in sheep was 56.4 and 68.4% at 1 and 2 mg/kg respectively; whereas 1 mg/kg of sulphoxide metabolite induced an efficacy of 73.9%. The HPLC assays performed showed no evidence of the sulphoxide and sulphone metabolites. It is concluded that besides solubility and high in vitro fasciolicidal efficacy, the in vivo results in sheep showed only a moderate efficacy.


REFERENCES

  1. ENCINAS GR, QUIROZ RH, GUERRERO MC, OCHOA GP. Frecuencia de fasciolasis hepática e impacto económico en bovinos sacrificados en Ferrería México, D.F. Vet Méx 1989; 20:423-426.

  2. CASTELLANOS HAA, ESCUTIA SI, QUIROZ RH. Frecuencia de fasciolasis hepática en bovinos sacrificados en las plantas tipo inspección federal en México de los años 1979-1987. Vet Méx 1992;23:339-342.

  3. RANGEL RLJ, MARTÍNEZ DE. Pérdidas económicas por decomiso de hígados y distribución geográfica de la fasciolasis bovina en el estado de Tabasco, México. Vet Méx 1994;25:327-331.

  4. FAIRWEATHER I, BORAY JC. Fasciolicides: Efficacy, Actions, Resistance and its Management. Vet J 1999;158:81-112.

  5. HERNANDEZ CA, IBARRA VF, VERA MY, RIVERA FN, CASTILLO BR. Synthesis and Fasciolicidal Activity of 5-chloro-2-methylthio-6-(1-naphthyloxy)-1Hbenzimidazole. Chem Pharm Bull 2002; 50: 649-652.

  6. IBARRA VF, VERA MY, HERNÁNDEZ CA, CASTILLO BR. Eficacia de un compuesto experimental contra Fasciola hepatica juvenil y adulta en ganado ovino. Vet Méx 1996; 27:119-122

  7. IBARRA VF, VERA MY, HERNÁNDEZ CA, CASTILLO BR. Eficacia fasciolicida del compuesto "alfa" contra estadios juveniles y adultos en ovinos. Vet Méx 1997b;28:297- 301.

  8. RIVERA FN, IBARRA VF, OLAZARÁN JS, VERA MY, CASTILLO BR, HERNÁNDEZ CA. Eficacia del 5-chloro-2-methylthio-6-(1-naphthyloxy) benzimidazole contra diversas edades de Fasciola hepatica en ovinos. Vet Méx 2002; 33: 55 – 61.

  9. IBARRA VF, MONTENEGRO CN, FLORES CJ, HERNÁNDEZ CA, CASTILLO BR. Evaluación de 4 vehículos para formular un fasciolicida experimental. Vet Méx 2000b;31: 47 - 51.

  10. IBARRA VF, CRISTINO MN, VERA MY, CASTILLO BR, HERNÁNDEZ CA, OCHOA GP. Eficacia comparativa de un fasciolicida experimental, triclabendazol y closantel en bovinos infectados en forma natural con Fasciola hepatica. Vet Méx 2002; 33: 237-245.

  11. IBARRA FV, VERA MY, QUIROZ RH, CANTO J, CASTILLO BR, HERNANDEZ A et al. Determination of the effective dose of an experimental fasciolicide in naturally and experimentally infected cattle. Vet Parasit 2004;120: 65-74.

  12. LO P, FINK D, WILLIAMS J, BLODINGER J. Pharmacokinetics studies of invermectin effect of formulation. Vet Res Com 1985;9: 251-268.

  13. 13.WICKS S, KAYE B, WEATHERLEY A, LEWIS D, DAVISON E, GIBSON S et al. Effect formulation the pharmacokinetics and efficacy of doramectin. Vet Parasitol 1993;49: 17-26.

  14. EVARD A, CHIAP P, TULLIO PD, GHALMI F, PIEL G, VAN HESS T et al. Oral bioavailability in sheep of albendazole from a suspension and from solution containing hydroxypropyl beta cyclodextrin. J Control Release 2002; 85: 45-50.

  15. ATHANASSIOU G. Antimicrobial activity of beta-lactamantibiotics against clinical pathogens after molecular inclusion in several cyclodextrins. A novel approach to bacterial resistance J Pharm Pharmacol 2003; 55:291–300.

  16. NAKAMURA K. Potential use of cyclodextrins to enhance the solubility of YM466 in aqueous solution. Drug Dev Ind Pharm 2003;29: 903–908.

  17. ZINGONE G, RUBESSA F. Preformulation study of the inclusion complex warfarin-beta-cyclodextrin. Int J Pharm 2005; 291: 3-10.

  18. RIVERO LM, JUNG H, CASTILLO R, HERNANDEZ CA. High-performance liquid chromatographic assay for a new fasciolicide agent, αBIOF10, in biological fluids. J Chromatogr B: Biom Sci Applic 1998; 72;237-241.

  19. RIVERA N, IBARRA F, ZEPEDA A, FORTOUL T, CANTO G, HERNANDEZ A et al. The effect of the 5-chloro-2-methylthio-6-(1-naphtyloxy)-1H-benzimidazole called compound alpha on the tegument of immature Fasciola hepatica in its natural host. Parasitol Res 2005; 95:379-382.

  20. IBARRA QF, JENKINS DC. An in vitro screen for new fasciolicidal agents. Z Parasitenkd 1984; 70:655-661.

  21. RIVERA N, IBARRA F, ZEPEDA A, FORTOUL T, HERNANDEZ A, CASTILLO R. Tegumental surface changes in adult Fasciola hepatica following treatment in vitro and in vivo with an experimental fasciolicide. Parasitol Res 2004; 93:283-286.

  22. LINARES G. Análisis de Datos. La Habana: Universidad de la Habana, 1990.

  23. MERCOLINI L, COLLIVA C, AMORE M, FANALI S, AUGUSTA RM. HPLC analysis of the antidepressant trazadote and its main metabolite m-CPP in human plasma. J Pharm biomed Anal 2008;47:882-887.

  24. MINISTRY OF AGRICULTURE, FISHERIES AND FOOD MANUAL OF VETERINARY PARASITOLOGICAL LABORATORY TECHNIQUES. Technical Bulletin No. 18. Her Majesty´s Stationery Office. London, Great Britain: MAFF, 1988.

  25. WOOD IB, AMARAL NK, BAIRDEN K, DUNCAN JL, KASSAI J, MALONE JB et al. World association for the advancement of veterinary parasitology (WAAVP), second edition of guidelines for evaluating the efficacy of anthelmintics in ruminants. Vet Parasitol 1995;58:181-213.

  26. ZAR JH. Biostatistical Anaylsis. NJ: Ed. Prentice- Hall,1996.

  27. GARCIA JJ, BOLAS F, TORRADO JJ. Bioavailability and efficacy characteristics of two different oral liquid formulation of albendazole. Int J Pharm 2003; 250:351-358.

  28. RAGHAVAN R, JOSEPH JC. Chromatographic methods of analisys-High-Performance Liquid Chromatography. 2nd ed. Encyclopedia of Pharmaceutical Technology. New York: Informa Health Care,. 2002:414-425.

  29. BREWSTER ME, LOFTSSON T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 2001;59:645-666.

  30. PITHA J, MILECKI J, FALES H, PANNELL, UEKAMA K. Hydroxypropyl-β-cyclodextrin: preparation and characterization; effects on solubility of drugs. Int J Pharm 1986;29:73–82.

  31. WALECZEK KJ, CABRAL MHM, HEMPEL B, SCHMIDT PC. Phase solubility studies of pure (-) alga-bisabolol and chamomile essential oil beta-cyclodextrin. Eur J Pharm Biopharm 2003; 55: 247-251.

  32. RONG-KUN CH, AMIR HS. Effect of Hydroxypropyl B-cyclodextrin on drug solubility in water-propylene glycol mixtures. Drug Dev Ind Pharm 2004;30:297-302.

  33. SANDERSON DM. A note on glycerol formal as a solvent in toxicity testing. J Pharm Pharmacol 1959;11:150-156.

  34. KYU-BONG K, SATHANANDAM SA, SRINIVASA M, HYO JK, JAMES VB. Formulation-dependent toxicokinetics explains differences in the GI absorption, bioavailability and acute neurotoxicity of deltamethrin in rats. Toxicology 2007;234:194-202.

  35. SIMAMORA P, ALVAREZ JM, YALKOWSKY SH. Solubilization of rapamycin. Int J Pharm 2001;213: 25-29.

  36. LIFSCHITZ A, VIRKEL G, BALLENT M, SALLOVITZ J, IMPERIALE F, PIS A et al. Ivermectin (3.15%) long acting formulations in cattle: absorption pattern and pharmacokinetic considerations. Vet Parasitol 2007;147: 303-310.

  37. BJERREGAARD S, PEDERSEN H, VEDSTESEN H, VERMEHREN C, SODERBERG I, FROKJAER S. Parenteral water/oil emulsions containing hydrophilic compound with enhanced in vivo retention: formulation, rheological characterization and study of in vivo fate using whole body gamma-scintingraphy. Int J Pharm 2001;215:13-27.

  38. ZUIDEMA J, PIETERS FAJM, DUCHATEAU GSMJE. Release and absorption rate aspects of intramuscular injected pharmaceuticals. Int J Pharm 1988;47:1-2.

  39. ZUIDEMA J, KADIR F, TILULAER HAC, OUSSOREN C. Release and absorption rate aspects of intramuscular injected pharmaceuticals. II. Int J Pharm 1994;105:189-207.

  40. FERRE PJ, LAROUTE V, BRAUN JP, CAZAUX J, TOUTAIN PL, LEFEBVRE HP. Simultaneous and minimally invasive assessment of muscle tolerance and biovailability of different volumes of an intramuscular formulation in the same animals. J Anim Sci 2006;84:1295-1301.

  41. FLOYD AG. Top ten considerations in the development of parenteral emulsions. Pharm Sci & Tech Today 1999;2:134-143.




2020     |     www.medigraphic.com